The invention discloses a novel application of jatrorrhizine for treating candida albicans infectious diseases. The jatrorrhizine can be extracted from plants of coptis roots, amur corktree barks, caulis mahoniae and the like. The study shows that half bacteriostasis concentration of the jatrorrhizine to candida albicans is 139+/-21mg/L, and effective dose of the jatrorrhizine for enhancing body resistibility of a low immune function mouse to the candida albicans is 30mg/Kg. The jatrorrhizine and pharmaceutically acceptable salts, esters or sugars, excipients and the like are utilized for preparing medicines for treating diseases caused by the fact that the candida albicans infect human and livestock, and the jatrorrhizine can be applied to, but is not limited to, medicines for treating human skins, mucous membranes, internal organs or nervous centralis candidiasis, livestock upper digestive tract mycoses and the like. The jatrorrhizine and the pharmaceutically acceptable salts, esters or sugars and excipients and the like can be prepared to be injection, oral administration and external preparations and dosage forms thereof which are pharmaceutically acceptable such as injections, tablets, capsules, liniments, pastes, smearing agents, emulsions, nanoparticle emulsions, and the like.